Evidence map›Paper›PMID 36408174›Full record

ArticleFrontiers in oncology2022

DJ-1 promotes osteosarcoma progression through activating CDK4/RB/E2F1 signaling pathway.

Zhitao Han, Lining Wang, Dongshuo Wang, Luosheng Zhang, Yifeng Bi, Xinlei Zheng, Weibo Liu, Guangjian Bai, Zhenhua Wang, Wei Wan and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Journal of immunology research · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Zhitao HanSchool of Chinese Medicine, School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Lining WangSchool of Chinese Medicine, School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Dongshuo WangSchool of Chinese Medicine, School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Luosheng ZhangDepartment of Orthopedic Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Yifeng BiDepartment of Orthopedic Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Xinlei ZhengSchool of Chinese Medicine, School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Weibo LiuDepartment of Orthopaedics, the Fourth Medical Centre, Chinese PLA General Hospital, Beijing, China.
Guangjian BaiDepartment of Orthopedic Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Zhenhua WangDepartment of Laboratory Medicine, Changzheng Hospital, Naval Medical University, Shanghai, China.
Wei WanDepartment of Orthopedic Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Yong MaSchool of Chinese Medicine, School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Xiaopan CaiDepartment of Orthopedic Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Tielong LiuDepartment of Orthopedic Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Qi JiaDepartment of Orthopedic Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Shanghai Changzheng Hospital · CNNanjing University of Chinese Medicine · CNChinese PLA General Hospital · CNSecond Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OS) is a primary malignant tumor of the bone characterized by poor prognosis due to chemotherapy resistance and high recurrence rates. DJ-1 (PARK7) is known as an oncogene and its abnormal expression is related to the poor prognosis of various types of malignant tumors. It was found in this study that upregulated expression of DJ-1 was closely correlated with the prognosis of OS patients by promoting the proliferation, migration and chemotherapy resistance of OS cells

Indexed as

cdk4DJ-1 (PARK7)E2F1osteosarcoma (OS)RBtarget therapy

Identifiers

PMID36408174
PMCPMC9671360
OpenAlexW4308417201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.